Clinical trials: Tace
Cholangiocarcinoma Non-resectable
Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the feasibility and safety of drug eluting beads-transcatheter arterial chemoembolization combined with lenvatinib and pucotenlimab as…
- Trial name
- CCGLC-012 (NCT06192784)
- Testing
- DEB-TACE, Lenvatinib plus pucotenlimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma, Liver Neoplasms
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death that ranks sixth in terms of incident cases, with an overall 5 years survival of 18%.
- Conditions
- Hepatocellular Carcinoma, Liver Neoplasms, Digestive System Neoplasms, Sorafenib
- Trial name
- NCT04518852
- Testing
- TACE combined with sorafenib and PD-1 mAb
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Hepatocellular Carcinoma
Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
To evaluate safety and efficacy of combined hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin and sorafenib in hepatocellular carcinoma (HCC) refractory to transarterial…
- Trial name
- NCT03722498
- Testing
- HAIC of FOLFOX, Sorafenib
- Where
- 3 sites in China
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular
Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
The purpose of the study is to determine whether transarterial chemoembolization containing arsenic trioxide is safe and effective in the treatment of intermediate-stage hepatocellular carcinoma.
- Trial name
- SEATH (NCT02018757)
- Testing
- TACE containing As2O3
- Where
- 5 sites in China
- Volunteers
- 250 people
- Sponsor
- First Hospital of China Medical University
Hepatocellular Carcinoma
TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)
For patients with advanced HCC not suitable for resection or liver transplantation but without extrahepatic manifestations, local therapy with TACE is regarded as standard treatment.
- Trial name
- SOCRATES (NCT00618384)
- Testing
- Sorafenib
- Where
- 6 sites in Germany
- Volunteers
- 43 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Carrelizumab Plus Lenvatinib Combined With TACE, Borderline Resectable Hepatocellular Carcinoma
The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC
The effectiveness and safety of carmelizumab/lenvatinib combined with TACE in patients with borderline resectable hepatocellular carcinoma remain unknown.
- Trial name
- NCT05042336
- Testing
- camrelizumab/lenvatinib combined with TACE
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Sichuan University
Hepatocellular Carcinoma (HCC)
TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with Tislelizumab and Lenvatinib in patients with advanced-stage hepatocellular carcinoma (HCC).
- Trial name
- CHANCE2602 (NCT07836309)
- Where
- China
- Volunteers
- 596 people
- Sponsor
- Zhongda Hospital
HCC
TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
This study is a prospective phase II, single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of the sequential administration of trans-arterial chemo-embolization (TACE)…
- Trial name
- NCT04988945
- Testing
- TACE, SBRT, Durvalumab
- Where
- 2 sites in Hong Kong
- Volunteers
- 33 people
- Sponsor
- The University of Hong Kong
Hepatocellular Carcinoma
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE combined with Lenvatinib in the treatment of patients with BCLC stage B and C HCC.Treatment will continue until the death or intolerable…
- Trial name
- NCT04490694
- Testing
- Lenvatinib, TACE
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma (HCC)
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary efficacy of a combination therapy involving TACE, sintilimab, bevacizumab, and ipilimumab N01 for the treatment of advanced hepatocellular…
- Trial name
- NCT07422753
- Testing
- CTLA-4 Antibody(ipilimumab N01)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma
Study in Asia of the Combination of TACE With Sorafenib in HCC Patients
TACE possibly plays a significant role in contributing to a subgroup of surviving residual tumor tissue which is characterized by more aggressive biology.
- Trial name
- START (NCT00990860)
- Testing
- doxorubicin, TACE (Transcatheter arterial chemoembolization)
- Where
- 8 sites in Taiwan
- Volunteers
- 36 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Colorectal Cancer
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
The primary objective of this study is to evaluate the efficacy of Irinotecan Beads in combination with intravenous cetuximab versus intravenous irinotecan in combination with intravenous cetuximab in the treatment of patients…
- Trial name
- DEBIRITUX (NCT01060423)
- Testing
- Cetuximab, Irinotecan, Irinotecan eluting BEADS
- Where
- 13 sites in Germany
- Volunteers
- 8 people
- Sponsor
- Hans-Joachim Schmoll, MD
Chronic Hepatitis B, Hepatocellular Carcinoma
Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common solid cancers worldwide, and chronic hepatitis B virus (HBV) infection is the most common etiology of HCC in Asia.
- Trial name
- NCT01872988
- Testing
- Tenofovir
- Where
- 4 sites in Taiwan
- Volunteers
- 320 people
- Sponsor
- Taichung Veterans General Hospital
Hepatocellular Carcinoma Non-resectable
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus TACE (Len-Sin-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05608200
- Testing
- Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma
Background Hepatocellular carcinoma, a malignant tumor of liver is one of the most common cancers worldwide. All India Institute Of Medical Sciences (AIIMS) being a tertiary care hospital receives about two to three cases of…
- Trial name
- NCT00522405
- Testing
- TACE
- Where
- India
- Sponsor
- All India Institute of Medical Sciences
Hepatocellular Carcinoma
Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma
The purpose of this study is to evaluate efficacy, safety, and patient reported outcomes (PRO) of different regimens of transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).
- Trial name
- TACEforHCC (NCT00493402)
- Testing
- Transarterial chemoembolization (TACE)
- Where
- China
- Volunteers
- 365 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
This research is being done to find out if using the contrast agent MultiHance can be used to show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial Chemoembolization (TACE).
- Trial name
- TACE (NCT00539253)
- Testing
- gadobenate dimeglumine (MultiHance)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
This study is conducted to evaluate the efficacy and safety of lenvatinib plus transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX regemen…
- Trial name
- NCT06492395
- Testing
- Len+DEB-TACE+HAIC, Len+DEB-TACE
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Colorectal Neoplasms Malignant
TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy.
- Trial name
- TACE-Ax-HCQ (NCT04873895)
- Testing
- Axitinib 5 MG, Hydroxychloroquine Pill, trans arterial chemoembolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Unresectable Intrahepatic Cholangiocarcinoma
Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma
The goal of this clinical trial is to learn about the combined therapy using drug-eluting bead-transarterial chemoembolization (D-TACE), gemcitabine (Gem) and cisplatin (Cis) chemotherapy, and PD-1 antibody in patients with…
- Trial name
- NCT05738057
- Testing
- Camrelizumab, Gemcitabine Injection, Cisplatin injection
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Hua Li